How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?

References

• IARC., http://www-dep.iarc.fr/.; 2012.
   Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005;25:696–703.
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen DS. Recent research progress in hepatocellular carcinoma. J Formos Med Assoc. 2002;101:239–248.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Kao JH. Hepatitis C virus infection in Taiwan: past, present and future. J Formos Med Assoc. 2015. doi:10.1016/j.jfma.2015.06.012.
   Web of Science ®Google Scholar
• Lin CL, Kao JH. Perspectives and control of hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2015;114:901–909.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824–1833.
   PubMed Web of Science ®Google Scholar
• Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015;28:55–65.
   PubMedGoogle Scholar
• Wang CC, Tseng KC, Peng CY, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013;28:46–50.
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Longterm entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.
   PubMed Web of Science ®Google Scholar
• Lin SM, Sheen IS, Chien RN, et al. Long term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–232.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–967.
   PubMed Web of Science ®Google Scholar
• Shimomura S, Ikeda N, Saito M, et al. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int. 2010;5:559–566.
   PubMed Web of Science ®Google Scholar
• Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72(Suppl 1):132–138.
   PubMed Web of Science ®Google Scholar
• Tsujita E, Maeda T, Kayashima H, et al. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma. Hepatogastroenterology. 2015;62(137):157–63.
   PubMed Web of Science ®Google Scholar
• Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197–1204.
   PubMed Web of Science ®Google Scholar
• Sakae M, Kubo S, Takemura S, et al. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2012;42:564–573.
   PubMed Web of Science ®Google Scholar
• Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2012;57:1092–1101.
   PubMed Web of Science ®Google Scholar
• Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–1559.
   PubMed Web of Science ®Google Scholar
• Saito T, Chiba T, Suzuki E, et al. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci. 2014;11:707–712.
   PubMed Web of Science ®Google Scholar
• Tsujita E, Yamashita Y, Takeishi K, et al. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C. Hepatogastroenterology. 2013;60:2048–2054.
   PubMed Web of Science ®Google Scholar
• Jeong SC, Aikata H, Katamura Y, et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol. 2007;13:5343–5350.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001;92:59–66.
   PubMedGoogle Scholar
• Uenishi T, Nishiguchi S, Tamori A, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195–200.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–1554.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–422.
   PubMed Web of Science ®Google Scholar
• Miyaguchi S, Watanabe T, Takahashi H, et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology. 2002;49:724–729.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Higuchi K, Kubota T, et al. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 2012;59:529–532.
   PubMed Web of Science ®Google Scholar
• Tanimoto Y, Tashiro H, Aikata H, et al. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 2012;19:418–425.
   PubMed Web of Science ®Google Scholar
• Jeong S, Aikata H, Katamura Y, et al. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol. 2007;13:5188–5195.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Chao YC, Lin HH, et al. Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep. 2015;5:9954. doi:10.1038/srep09954.
   PubMed Web of Science ®Google Scholar
• Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–858.
   PubMed Web of Science ®Google Scholar
• Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14:6140–6144.
   PubMed Web of Science ®Google Scholar
• Zhang W, Song TQ, Zhang T, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–1134.
   PubMedGoogle Scholar
• Zhuang L, Zeng X, Yang Z, et al.. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361.
   PubMed Web of Science ®Google Scholar
• Sun P, Yang X, He RQ, et al. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: a systematic review of randomized trials. Hepatol Res. 2014;44:259–269.
   PubMed Web of Science ®Google Scholar
• Xu JB, Qi FZ, Xu G, et al. Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2014;44:209–217.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JW, Koh DW, et al. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. Liver Int. 2009;29:203–207.
   PubMed Web of Science ®Google Scholar
• Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma–using an untreated, matched control cohort. Acta Med Okayama. 2005;59:217–224.
   PubMed Web of Science ®Google Scholar
• Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663–1673.
   PubMed Web of Science ®Google Scholar
• Goto T, Yoshida H, Tateishi R, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011;5:767–773.
   PubMed Web of Science ®Google Scholar
• Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44:991–999.
   PubMed Web of Science ®Google Scholar
• Su CW, Chiou YW, Tsai YH, et al. The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. PLoS One. 2013;8:e66457.
   PubMed Web of Science ®Google Scholar
• Urata Y, Kubo S, Takemura S, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685–696.
   PubMed Web of Science ®Google Scholar
• Kubo S, Tanaka H, Takemura S, et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res. 2007;37:94–100.
   PubMed Web of Science ®Google Scholar
• Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33:1104–1112.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906–14.
   PubMed Web of Science ®Google Scholar
• Yeh YC, Liu CJ, Kuo RN, et al. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One. 2014;9:e102051.
   Google Scholar
• Xia BW, Zhang YC, Wang J, et al. Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:458–468.
   PubMed Web of Science ®Google Scholar
• Lee TY, Lin JT, Zeng YS, et al.. Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2015 Oct 1. DOI:10.1002/hep.28266.
   Google Scholar
• Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929–1935.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Yoshida H, Goto E, et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int. 2008;2:89–94.
   PubMed Web of Science ®Google Scholar
• Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med. 2009;48:11–17.
   PubMed Web of Science ®Google Scholar
• Ke Y, Ma L, You XM, et al. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013;10:158–164.
   PubMedGoogle Scholar
• Nishikawa H, Nishijima N, Arimoto A, et al. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608–620.
   PubMed Web of Science ®Google Scholar
• Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17:179–185.
   PubMed Web of Science ®Google Scholar
• Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology. 2006;53:249–252.
   PubMed Web of Science ®Google Scholar
• Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011;146:675–681.
   PubMed Web of Science ®Google Scholar
• Huang G, Yang Y, Shen F, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol. 2013;20:1482–1490.
   PubMed Web of Science ®Google Scholar
• Sun P, Dong X, Cheng X, et al. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761.
   PubMedGoogle Scholar
• Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261:56–66. doi:10.1097/SLA.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Zhou ZQ, Zhou GW. Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm. Eur J Gastroenterol Hepatol. 2014;26:1116–1124.
   PubMed Web of Science ®Google Scholar
• Ke Y, Wang L, Li LQ, et al.. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol. 2014;6:652–659.
   PubMedGoogle Scholar
• Liu GM, Huang XY, Shen SL, et al.. Adjuvant antiviral therapy for HBV-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. Hepatol Res. 2015 Aug 29; doi:10.1111/hepr.12584.
   Web of Science ®Google Scholar
• Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647–3655.
   PubMed Web of Science ®Google Scholar
• Qu LS, Jin F, Huang XW, et al.. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg. 2010;14:1111–1120.
   PubMed Web of Science ®Google Scholar
• Someya T, Ikeda K, Saitoh S, et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2006;41:1206–1213.
   PubMed Web of Science ®Google Scholar
• Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8–17.
   PubMed Web of Science ®Google Scholar
• Sun HC, Tang ZY, Wang L, et al. Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–465.
   PubMed Web of Science ®Google Scholar
• Qu LS, Jin F, Huang XW, et al.. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitic B virus-related hepatocellular carcinoma. J Surg Oncol. 2010;102:796–801.
   PubMed Web of Science ®Google Scholar
• Park JW, Park KW, Cho SH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol. 2005;100:2194–2200.
   PubMed Web of Science ®Google Scholar
• Lao XM, Wang D, Shi M, et al. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res. 2011;41:553–563.
   PubMed Web of Science ®Google Scholar
• Peng JW, Lin GN, Xiao JJ, et al.. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol. 2012;8:356–361.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–240.
   PubMed Web of Science ®Google Scholar
• Lao XM, Luo G, Ye LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int. 2013;33:595–604.
   PubMed Web of Science ®Google Scholar
• Xu X, Huang P, Tian H, et al. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:1273–1278.
   PubMed Web of Science ®Google Scholar
• Zhu SL, Zhong JH, Ke Y, et al. Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. Tumour Biol. 2015;36:6277–6284.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:813–819.
   PubMed Web of Science ®Google Scholar
• Huang W, Zhang W, Fan M, et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma. Cancer Sci. 2014;105:697–703.
   PubMed Web of Science ®Google Scholar